We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

49 hedge funds and large institutions have $30.3M invested in Outlook Therapeutics in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 2

291% more capital invested

Capital invested by funds: $7.76M → $30.3M (+$22.5M)

63% more funds holding

Funds holding: 30 → 49 (+19)

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

0.15% more ownership

Funds ownership: 0.23% → 0.39% (+0.15%)

Holders
49
Holders Change
+19
Holders Change %
+63.33%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
12
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.51M
2
BlackRock
BlackRock
New York
+$3.34M
3
Two Sigma Investments
Two Sigma Investments
New York
+$2.04M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.49M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$906K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$188K
2
VF
Virtu Financial
New York
-$179K
3
Capstone Investment Advisors
Capstone Investment Advisors
New York
-$83.7K
4
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$35K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$30K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$9.37M +$3.51M +91,782 +79%
LA
2
LVW Advisors
New York
$3.92M – – –
BlackRock
3
BlackRock
New York
$3.92M +$3.34M +87,127 New
Two Sigma Investments
4
Two Sigma Investments
New York
$2.8M +$2.04M +53,321 +600%
Renaissance Technologies
5
Renaissance Technologies
New York
$1.87M +$1.49M +38,893 +1,422%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.67M +$906K +23,652 +176%
Two Sigma Advisers
7
Two Sigma Advisers
New York
$1.36M +$880K +22,985 +320%
Axa
8
Axa
France
$931K +$793K +20,700 New
Millennium Management
9
Millennium Management
New York
$450K +$37.2K +971 +11%
IA
10
IndexIQ Advisors
New York
$414K +$353K +9,206 New
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$402K -$188K -4,904 -35%
Citadel Advisors
12
Citadel Advisors
Florida
$397K +$170K +4,447 +102%
Northern Trust
13
Northern Trust
Illinois
$390K +$150K +3,927 +83%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$373K +$318K +8,292 New
ECM
15
ExodusPoint Capital Management
New York
$319K +$200K +5,215 +277%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$214K -$16K -417 -8%
Goldman Sachs
17
Goldman Sachs
New York
$194K +$77.5K +2,023 +88%
Marshall Wace
18
Marshall Wace
United Kingdom
$182K +$155K +4,041 New
Osaic Holdings
19
Osaic Holdings
Arizona
$147K -$6.13K -160 -5%
LP
20
LMR Partners
United Kingdom
$124K +$105K +2,749 New
Charles Schwab
21
Charles Schwab
California
$78K +$65.9K +1,722 New
HF
22
HRT Financial
New York
$64K +$54.9K +1,434 New
TRCT
23
Tower Research Capital (TRC)
New York
$55K +$33.7K +881 +261%
Morgan Stanley
24
Morgan Stanley
New York
$53K -$2.68K -70 -6%
Creative Planning
25
Creative Planning
Kansas
$53K – – –
1
2 3

OTLK Hedge Fund Activity: Q1 2021 in Review

49 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2021, worth a combined $30.3M — up 291% from $7.76M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new OTLK positions and 2 closed out — a net gain of 19 holders — while 12 added to existing stakes and 8 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.51M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $188K.

  • 49 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2021, up from 30 in Q4 2020.
  • Funds reported $30.3M of Outlook Therapeutics stock for Q1 2021, up 291% quarter-over-quarter.
  • 21 funds opened new Outlook Therapeutics positions in Q1 2021 and 2 closed out, a net change of +19 holders.
  • The largest Outlook Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $3.51M added.
  • The largest Outlook Therapeutics seller in Q1 2021 was Jacobs Levy Equity Management, an estimated $188K sold.

Based on aggregated 13F filings for Q1 2021.